【光大研究每日速递】20250710

Transportation Industry - In H1 2025, geopolitical events disrupted freight rates, with Q2 rates showing a downward trend compared to Q1. The June Israel-Palestine conflict led to a temporary spike in rates due to the blockade of the Strait of Hormuz. As of June 30, 2025, the BDTI composite index was at 984 points, up 15.4% year-to-date, while the BDTI TD3C-TCE reported $29,300 per day, an increase of 37.0% year-to-date [4]. Honglu Steel Structure (002541.SZ) - In Q2 2025, Honglu Steel Structure showed stable operational performance with double-digit growth in both order volume and production. The company's solutions in intelligent cutting and welding have matured and entered large-scale deployment. Q2 production reached a historical high, indicating initial success in smart transformation, which is expected to enhance capacity utilization, reduce production costs, and strengthen competitive advantages in the long term [4]. Qutai Technology (1478.HK) - In June, Qutai Technology's mobile camera module shipments reached 32.648 million units, reflecting a 0.8% month-on-month increase and a 1.5% year-on-year increase, marking two consecutive months of growth. In H1 2025, total shipments were 183.866 million units, down 14.8% year-on-year, attributed to the company's focus on high-end products and reduction in low-end product shipments [5][6]. Tencent Music (TME.N) - Tencent Music is solidifying its competitive barriers while innovating subscription models and features. The development of SVIP is expected to boost ARPPU, and non-subscription revenue from advertising, ticket sales, and digital albums is anticipated to contribute additional growth. However, the impact of subscription business innovations remains cautious due to the unclear timeline for the Himalaya delivery schedule [7]. Changchun Gaoxin (000661.SZ) - Recently, Changchun Gaoxin's injection of Vuxin Qibai monoclonal antibody was approved for market release, marking it as the first IL-1 inhibitor approved for treating acute attacks of gouty arthritis in adults in China. This approval is a significant achievement in the company's ongoing innovation transformation, which has seen rapid growth in R&D and sales expenses since 2024, enhancing its innovation pipeline and commercialization capabilities [7].